| Standing pat. The RBA is set to hold interest rates again today as easing inflation gives the central bank more time to assess the impact of its policy tightening. It's a different story for the Fed and the ECB, which are both expected to push rates higher this week. Australian house prices rose for a second consecutive month in April, suggesting a stabilization that's coincided with the rate rise pause. Clinuvel is limiting availability of a drug to treat a rare skin disease. The Melbourne-based company is an outlier in the pharmaceutical industry in that it keeps tight control over who can administer its drug, known as Scenesse. It also discourages patients from participating in trials of other treatments. The lucky country. Australia's fiscal coffers are rapidly refilling as high commodity prices and near-full employment bring windfall tax revenue, raising the possibility that next week's budget could post the first surplus in 15 years. The country's underlying budget position was better than forecast in the nine months through March, government data show.
Brookfield Asset Management aims to raise more than $15 billion for a new fund to invest in low-carbon technologies. It will invest in emerging technologies like green hydrogen and carbon capture, alongside more established investments in wind, solar and batteries. In March, Brookfield led a consortium that agreed to acquire Australian utility Origin Energy, and plans to invest A$20 billion ($13.3 billion) over the next decade to add clean energy generation. |
No comments:
Post a Comment